A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Recruiting

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(37 sites)

United Kingdom

Royal Bournemouth Hospital, Bournemouth

Royal Sussex County Hospital, Brighton

Bristol Haematology and Oncology Centre, Bristol

Queen's Hospital, Burton-on-Trent

Cambridge University Hospitals NHS Foundation Trust, Cambridge

East Kent Hospitals University NHS Foundation Trust, Canterbury

Velindre Cancer Centre, Cardiff

Colchester Hospital, Colchester

Royal Derby Hospital, Derby

NHS Lothian, Edinburgh

Royal Devon and Exeter Hospital, Exeter

Beatson West of Scotland Cancer Centre, Glasgow

New Victoria Hospital, Glasgow

Royal Surrey NHS Foundation Trust, Guildford

Calderdale & Huddersfield NHS Foundation Trust, Huddersfield

Ipswich Hospital, Ipswich

Kettering General Hospital, Kettering

NHS Fife, Kirkcaldy

Forth Valley Royal Hospital, Larbert

Leeds Teaching Hospitals NHS Trust, Leeds

Leicester Royal Infirmary, Leicester

The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool

Guys Hospital, London

Imperial College Healthcare NHS Trust, London

North Middlesex University Hospital NHS Trust, London

St Bartholomew's Hospital, London

The Christie NHS Foundation Trust, Manchester

Northampton General Hospital NHS Trust, Northampton

Nottingham University Hospitals NHS Trust, Nottingham

Peterborough City Hospital, Peterborough

Poole Hospital, Poole

Queen's Hospital, Barking Havering and Redbridge University Hospitals NHS Trust, Romford

Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield

The Royal Marsden NHS Foundation Trust, Sutton

Royal Cornwall Hospital, Truro

Worthing Hospital, Worthing

Yeovil Hospital, Yeovil